| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/27/2005 | WO2005007098A2 Nucleic acid therapy to enhance cartilage repair |
| 01/27/2005 | WO2005006958A2 Modulation of ceacam1 expression |
| 01/27/2005 | WO2005006864A1 Genetic vaccines for cancer therapy |
| 01/27/2005 | WO2004074514A3 Method of diagnosis of type 2 diabetes and early onset thereof |
| 01/27/2005 | WO2004067707A3 Administration of transposon-based vectors to reproductive organs |
| 01/27/2005 | WO2003087374A9 Derivatives of the il-2 receptor gamma chain, their production and use. |
| 01/27/2005 | WO2003087334A3 Use of aav integration efficiency element for mediating site-specific integration of a transcription unit |
| 01/27/2005 | WO2003076565A3 Methods of using 46828, a human acyl-coa synthetase |
| 01/27/2005 | WO2003031594A3 Nucleotide and amino acid sequences relating to respiratory diseases and obesity |
| 01/27/2005 | US20050021091 System for the delivery of a biologic therapy with device monitoring and back-up |
| 01/27/2005 | US20050021089 Compositions and methods for treating cardiac dysfunction |
| 01/27/2005 | US20050020531 Systemic carnitine deficiency gene and uses thereof |
| 01/27/2005 | US20050020530 Treatment of parkinson's disease with oligonucleotides |
| 01/27/2005 | US20050020529 Delivery construct for antisense nucleic acids and methods of use |
| 01/27/2005 | US20050020527 Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders |
| 01/27/2005 | US20050020526 Oligodeoxynucleotide intervention for prevention and treatment of sepsis |
| 01/27/2005 | US20050020524 Immunostimulation during thymus reactivation treatment |
| 01/27/2005 | US20050020522 Induce mitrosis and smooth muscle proliferation; administering to cell or tissue a polynucleotide which codes endothelial growth factor |
| 01/27/2005 | US20050020521 In vivo gene silencing by chemically modified and stable siRNA |
| 01/27/2005 | US20050020520 DNA vaccine containing tumor-associated gene and cytokine gene and method of preparation the same |
| 01/27/2005 | US20050020519 Increase concentration of peptide; controlling glucose uptake into cells; adjust metabolism; stimulate cell proliferation; reduce apoptosis; moderate gene expression' |
| 01/27/2005 | US20050020518 under physiological conditions, containing a labile disulfide bond and a transduction signal such as transcriptional factor from Drosophila, ANTP; for the delivery of a compound to a cell; disulfide bond cleaved more rapidly than oxidized glutathione |
| 01/27/2005 | US20050019929 Deleted adenovirus vectors and methods of making and administering the same |
| 01/27/2005 | US20050019927 DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
| 01/27/2005 | US20050019926 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |
| 01/27/2005 | US20050019921 Method for combined sequential agent delivery and electroporation for cell structures and use thereof |
| 01/27/2005 | US20050019908 Post-partum mammalian placenta, its use and placental stem cells therefrom |
| 01/27/2005 | US20050019890 Nitrilase homologs |
| 01/27/2005 | US20050019889 Human osteoclast derived cathepsin |
| 01/27/2005 | US20050019872 PC-LECTIN protein; vaccines and diagnostic marker for prostate cancer |
| 01/27/2005 | US20050019866 Nucleotide sequences coding membrane protein for use in diagnosis, detection, prevention and/or treatment of cell proliferative disorders |
| 01/27/2005 | US20050019824 Fibroblast Growth Factor-10 |
| 01/27/2005 | US20050019812 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019811 Neutral amino acid transporter and gene thereof |
| 01/27/2005 | US20050019346 Nucleic acids and regulatory sequences; gene expression; antitumor agents |
| 01/27/2005 | US20050019313 Genetic engineering; supplying stem cells; genes code cytosine deaminase; central nervous system tumors |
| 01/27/2005 | US20050019308 Administering reovirus; lysis of cancer cells |
| 01/27/2005 | US20050019307 Therapy gene against mammary gland cancer; transcription control ; Dna |
| 01/27/2005 | US20050019304 Novel human mage-like protein |
| 01/27/2005 | CA2573060A1 Asymmetric disulfides and methods of using same |
| 01/27/2005 | CA2533199A1 Reactive polymers and copolymers, method of their preparation and their use |
| 01/27/2005 | CA2532630A1 Use of lymphocytes transformed with .alpha.-2-heremans-schmid glycoprotein (ahsg) to treat tgf-.beta.-mediated cancer |
| 01/27/2005 | CA2532595A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 01/27/2005 | CA2532228A1 Lipid encapsulated interfering rna |
| 01/27/2005 | CA2532216A1 Oligodendrocyte precursor cells and methods of obtaining and culturing the same |
| 01/27/2005 | CA2532138A1 Injection of bone marrow-derived cells and medium for angiogenesis |
| 01/27/2005 | CA2531069A1 Inhibition of syk kinase expression |
| 01/27/2005 | CA2516652A1 System for external control of oncolytic virus replication |
| 01/26/2005 | EP1500702A1 APO-2LI and APO-3 apoptosis polypeptides from the TNFR1 familiy |
| 01/26/2005 | EP1500399A1 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases |
| 01/26/2005 | EP1499886A1 Methods and compositions for inducing an immune response |
| 01/26/2005 | EP1499746A1 Method to inhibit cell growth using oligonucleotides |
| 01/26/2005 | EP1499736A1 Improved chimeric glycoproteins and pseudotyped lentiviral vectors |
| 01/26/2005 | EP1499735A2 Optimization of transgene expression in mammalian cells |
| 01/26/2005 | EP1499731A2 Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy |
| 01/26/2005 | EP1499730A1 Immunoconjugates for the treatment of tumours |
| 01/26/2005 | EP1499729A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use |
| 01/26/2005 | EP1499724A1 Derivatives of the il-2 receptor gamma chain, their production and use |
| 01/26/2005 | EP1499721A1 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription factors |
| 01/26/2005 | EP1499362A1 Fusions of cytokines and tumor targeting proteins |
| 01/26/2005 | EP1499358A1 Ph-sensitive polymer |
| 01/26/2005 | EP1499355A2 Use of parapox b2l protein to treat cancer and modify immune responses |
| 01/26/2005 | EP1499350A2 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 01/26/2005 | EP1499349A2 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 01/26/2005 | EP1499340A2 Proteins involved in the regulation of energy homeostasis |
| 01/26/2005 | EP1499332A2 Compositions and methods for treating cancer with an oncolytic viral agent |
| 01/26/2005 | EP1499327A2 Beta -amyloid peptide-binding proteins and polynucleotides encoding the same |
| 01/26/2005 | EP1499190A2 Methods for treating liver disease and liver damage with growth hormone and foxm1b |
| 01/26/2005 | EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides |
| 01/26/2005 | EP1468094A4 Method of transducing es cells |
| 01/26/2005 | EP1430140A4 Isoform-selective inhibitors and activators of pde3 cyclic |
| 01/26/2005 | EP1315794A4 Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation |
| 01/26/2005 | EP1231926B1 Biomolecular complex formed between hyaluronic acid and a biomolecule, its method of manufacture and medical uses thereof |
| 01/26/2005 | EP1152009B1 Novel nucleosides and oligonucleotide analogues |
| 01/26/2005 | EP1149158A4 Genetic and epigenetic regulation of abc transporters and ect0-phosphatases for the modulation of drug resistance |
| 01/26/2005 | EP1127133B1 Polypeptide mediating cell permeability |
| 01/26/2005 | EP1061950B1 Live vaccine for human immunodeficiency virus |
| 01/26/2005 | EP1058558B1 Adjuvated, live recombinant vaccines against influenza- and herpesviruse |
| 01/26/2005 | EP1017835A4 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 01/26/2005 | EP1015595B1 Peptides derived from the attachment (g) protein of respiratory syncytial virus |
| 01/26/2005 | EP0934412B1 HUMAN THYMOSIN beta 15 GENE, PROTEIN AND USES THEREOF |
| 01/26/2005 | EP0886651B1 Persephin and related growth factors |
| 01/26/2005 | EP0769968B1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum |
| 01/26/2005 | EP0725826B1 Improvements relating to cancer therapy |
| 01/26/2005 | EP0652953B1 Morphogenic protein soluble complex and composition thereof |
| 01/26/2005 | CN1571844A Gene transfer into primate embryonic stem cells using VSV-G pseudo type simian immunodeficiency virus vectors |
| 01/26/2005 | CN1570122A Adenovirus vector for idiopathy liver genetherapy and using method |
| 01/26/2005 | CN1570101A Optimized SARS coronary virus N protein gene |
| 01/26/2005 | CN1569878A siRNA nucleic acid sequence for SARS coronavirus causing gene and its pharmaceutical use |
| 01/26/2005 | CN1569872A Antisense nucleic acid for inhibiting SARS virus gene expression and its use |
| 01/26/2005 | CN1569235A Thermotherapy for treating malignant solid tumour by promoting dendritic cell vaccine function |
| 01/26/2005 | CN1569234A Method for killing specific tumour cell by recin |
| 01/26/2005 | CN1569233A Method for manufacturing gene medicine for preventing and treating SARS and its medicinal prescription |
| 01/26/2005 | CN1569221A VEGF plasmid-liposome complex and its usage |
| 01/26/2005 | CN1186448C Recombinant human alpha-prothymosin interleukin 2 gene and its expression and use |
| 01/26/2005 | CN1186445C Light chain or heavy chain variable region gene of human liver cancer monoclonal antibody HAb18 and its application |
| 01/25/2005 | US6846911 An isolated protein comprising a soluble CD97 alpha subunit, and soluble subunit is selected from the group alpha 1, alpha 2, and alpha 3, originate as proprotein with beta subunit |
| 01/25/2005 | US6846883 Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
| 01/25/2005 | US6846809 Generating transfection liquids; obtain nutrient broths, incubate with nucleic acids, monitor ionic mobility, store |
| 01/25/2005 | US6846676 In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy |